Joint bone spine · 2026
Single-cell transcriptomics identifies CD36 as a negative regulator of osteogenic differentiation in murine osteoporosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Weibin, Han Xinyou, Fu Qingsong, Yuan Xinhua
Аннотация
BACKGROUND: Osteoporosis is characterized by impaired osteogenic differentiation of bone marrow mesenchymal stem cells (BM-MSCs). The molecular regulators driving this impairment in murine models remain incompletely understood.
OBJECTIVES: To identify key regulators of BM-MSC osteogenic differentiation in murine osteoporosis using single-cell transcriptomic analysis, and to validate the functional role of the identified candidate in vivo.
METHODS: Single-cell RNA sequencing data from murine osteoporosis and osteoarthritis samples were analyzed to identify differentially expressed genes in BM-MSC subpopulations. CD36 was selected based on GO-KEGG enrichment analysis. Functional validation was performed in an ovariectomy mouse model using adeno-associated virus-mediated CD36 knockdown. Bone microarchitecture was assessed by micro-computed tomography and histomorphometry. Osteogenic capacity was evaluated by Western blot, immunofluorescence, and immunohistochemistry.
RESULTS: CD36 was significantly upregulated in BM-MSCs from murine osteoporotic samples. CD36-positive BM-MSCs showed enrichment of the peroxisome proliferator-activated receptor signaling pathway and extracellular matrix-receptor interaction pathways. Adeno-associated virus-mediated CD36 knockdown in ovariectomized mice restored trabecular bone parameters and increased RUNX2-positive osteoprogenitor numbers compared to controls.
CONCLUSIONS: CD36 acts as a negative regulator of osteogenic differentiation in murine BM-MSCs. Targeting CD36 may represent a therapeutic strategy for osteoporosis by restoring the osteogenic/adipogenic balance in bone marrow.
OBJECTIVES: To identify key regulators of BM-MSC osteogenic differentiation in murine osteoporosis using single-cell transcriptomic analysis, and to validate the functional role of the identified candidate in vivo.
METHODS: Single-cell RNA sequencing data from murine osteoporosis and osteoarthritis samples were analyzed to identify differentially expressed genes in BM-MSC subpopulations. CD36 was selected based on GO-KEGG enrichment analysis. Functional validation was performed in an ovariectomy mouse model using adeno-associated virus-mediated CD36 knockdown. Bone microarchitecture was assessed by micro-computed tomography and histomorphometry. Osteogenic capacity was evaluated by Western blot, immunofluorescence, and immunohistochemistry.
RESULTS: CD36 was significantly upregulated in BM-MSCs from murine osteoporotic samples. CD36-positive BM-MSCs showed enrichment of the peroxisome proliferator-activated receptor signaling pathway and extracellular matrix-receptor interaction pathways. Adeno-associated virus-mediated CD36 knockdown in ovariectomized mice restored trabecular bone parameters and increased RUNX2-positive osteoprogenitor numbers compared to controls.
CONCLUSIONS: CD36 acts as a negative regulator of osteogenic differentiation in murine BM-MSCs. Targeting CD36 may represent a therapeutic strategy for osteoporosis by restoring the osteogenic/adipogenic balance in bone marrow.